Michael Enzo Furrow

Michael Enzo Furrow, Ph.D.


Partner, New York

Michael Furrow’s experience with and understanding of the challenges innate to discovery in the pharmaceutical and biotechnology fields fuels his passion to enforce and defend life sciences patents. He has represented innovators across these industries in high-stakes patent disputes both in Federal Court and before the U.S. Patent and Trademark Office, concerning drugs or biologics for treating HIV/AIDS, Alzheimer’s disease, breast cancer, epilepsy, and various endocrine, vascular and gastrointestinal diseases, as well as genetically modified animals. Michael’s experience covers all aspects of life sciences innovation, including new chemical entities, salt forms, prodrugs, solid state forms, dosage forms, combinations, methods of use, biologics and laboratory tools. In addition to his work in contested matters, he also has experience providing opinions on infringement and validity issues, and conducting due diligence in connection with patent-related business transactions.

Michael joined Fitzpatrick directly out of law school. He has published several articles in in the field of organic chemistry.

Additional Publications

"Pharmaceutical Patent Life-Cycle Management after KSR v. Teleflex," Food and Drug Law Journal, 2008.

"A General Procedure for the Esterification of Carboxylic Acids with Diazo-alkanes Generated In Situ by the Oxidation of N-tert-Butyldimethylsilylhydrazones with (Difluoroiodo) benzene," Journal of the American Chemical Society, 2004.

"Practical Procedures for the Preparation of N-tert-Butyldimethylsilyl-hydrazones and Their Use in Modified Wolff-Kishner Reductions and in the Synthesis of Vinyl Halides and gem-Dihalides," Journal of the American Chemical Society, 2004.

"Highly Selective Hydrolytic Kinetic Resolution of Terminal Epoxides Catalyzed by Chiral (salen) CoIII Complexes. Practical Synthesis of Enantioenriched Terminal Epoxides and 1,2-Diols," Journal of the American Chemical Society, 2002.

"Practical Access to Highly Enantioenriched C-3 Building Blocks via Hydrolytic Kinetic Resolution," Journal of Organic Chemistry, 1998.

"Practical Synthesis of Enantiomerically Enriched Glycidol by Kinetic Resolution of (±)-Epichlorohydrin and Dynamic Kinetic Resolution of (±)-Epibromohydrin," The Nucleus, 1998.

Case Highlight
Amgen et al. v. Teva Pharmaceuticals, et al.
D. Del. (2011)
Michael secured a victory in Hatch-Waxman litigation for Amgen and two other clients against two generic drug manufacturers. The district court ruled that Amgen’s drug Sensipar® for treating hyperparathyroud and carcinoma conditions were not invalid for anticipation, obviousness or double patenting, and had not been obtained through inequitable conduct before the U.S. Patent and Trademark Office.
Representative Matters
  • Salix Pharmaceuticals, Alfa Wassermann, Cedars-Sinai Medical Center, and Valeant Pharmaceuticals against a generic drug manufacturer in litigation on several families of patents covering the irritable bowel syndrome drug, Xifaxan®.  
  • Gilead Sciences and Emory University against various generic drug manufacturers in litigation on several families of patents covering the anti-HIV drugs Emtriva®, Viread®, Truvada® and Atripla®. 
  • AstraZeneca and KBI, Inc. against various generic drug manufacturers in litigation on various families of patents covering the proton pump inhibitor medicine Nexium® for gastric-acid related disorders. 
  • Amgen, NPS Pharmaceuticals, and Brigham & Women’s Hospital against various generic drug manufacturers in litigation on patents covering the calcimimetic Sensipar® for treating hyperparathyroid and carcinoma conditions. 
  • Novartis against Mylan in litigation on patents covering the breast cancer drug, Femara®, an aromatase inhibitor. 
  • Sanofi-Aventis and Bristol-Myers Squibb against various generic drug manufacturers in litigation and several reexamination proceedings on patents covering Plavix®, a leading anti-thrombotic agent.  
News & Press